Search

Objective. Reducing CT radiation dose is an often proposed measure to enhance patient safety, which, however results in increased image noise, translating into degradation of clinical image quality. Several deep learning methods have been proposed for low-dose CT (LDCT) denoising. The high risks posed by possible hallucinations in clinical images necessitate methods which aid the interpretation of deep learning networks. In this study, we aim to use qualitative reader studies and quantitative radiomics studies to assess the perceived quality, signal preservation and statistical feature preservation of LDCT volumes denoised by deep learning. We aim to compare interpretable deep learning methods with classical deep neural networks in clinical denoising performance. Approach. We conducted an image quality analysis study to assess the image quality of the denoised volumes based on four criteria to assess the perceived image quality. We subsequently conduct a lesion detection/segmentation study to assess the impact of denoising on signal detectability. Finally, a radiomic analysis study was performed to observe the quantitative and statistical similarity of the denoised images to standard dose CT (SDCT) images. Main results. The use of specific deep learning based algorithms generate denoised volumes which are qualitatively inferior to SDCT volumes( p < 0.05). Contrary to previous literature, denoising the volumes did not reduce the accuracy of the segmentation ( p > 0.05). The denoised volumes, in most cases, generated radiomics features which were statistically similar to those generated from SDCT volumes ( p > 0.05). Significance. Our results show that the denoised volumes have a lower perceived quality than SDCT volumes. Noise and denoising do not significantly affect detectability of the abdominal lesions. Denoised volumes also contain statistically identical features to SDCT volumes., (Creative Commons Attribution license.)

Background: To assess the additive value of dual-energy CT (DECT) over single-energy CT (SECT) to radiomics-based response prediction in patients with metastatic melanoma preceding immunotherapy., Material and Methods: A total of 140 consecutive patients with melanoma (58 female, 63±16 years) for whom baseline DECT tumor load assessment revealed stage IV and who were subsequently treated with immunotherapy were included. Best response was determined using the clinical reports (81 responders: 27 complete response, 45 partial response, 9 stable disease). Individual lesion response was classified manually analogous to RECIST 1.1 through 1291 follow-up examinations on a total of 776 lesions (6.7±7.2 per patient). The patients were sorted chronologically into a study and a validation cohort (each n=70). The baseline DECT was examined using specialized tumor segmentation prototype software, and radiomic features were analyzed for response predictors. Significant features were selected using univariate statistics with Bonferroni correction and multiple logistic regression. The area under the receiver operating characteristic curve of the best subset was computed (AUROC). For each combination (SECT/DECT and patient response/lesion response), an individual random forest classifier with 10-fold internal cross-validation was trained on the study cohort and tested on the validation cohort to confirm the predictive performance., Results: We performed manual RECIST 1.1 response analysis on a total of 6533 lesions. Multivariate statistics selected significant features for patient response in SECT (min. brightness, R²=0.112, padj. ≤0.001) and DECT (textural coarseness, R²=0.121, padj. ≤0.001), as well as lesion response in SECT (mean absolute voxel intensity deviation, R²=0.115, padj. ≤0.001) and DECT (iodine uptake metrics, R²≥0.12, padj. ≤0.001). Applying the machine learning models to the validation cohort confirmed the additive predictive power of DECT (patient response AUROC SECT=0.5, DECT=0.75; lesion response AUROC SECT=0.61, DECT=0.85; p<0.001)., Conclusion: The new method of DECT-specific radiomic analysis provides a significant additive value over SECT radiomics approaches for response prediction in patients with metastatic melanoma preceding immunotherapy, especially on a lesion-based level. As mixed tumor response is not uncommon in metastatic melanoma, this lends a powerful tool for clinical decision-making and may potentially be an essential step toward individualized medicine., Competing Interests: Competing interests: All authors declare no conflict of interest for this study. SF and AFC are employees of Siemens Healthcare and had no control over the data., (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)